SINGULAIR® (Montelukast sodium) is a drug for treating asthma, exercise-induced bronchoconstriction (EIB), and allergic rhinitis.

EicOsis Human Health has announced the advancement of its clinical research program, beginning a Phase 1b trial to assess the safety of its experimental drug, EC5026, through increasing dosages.

Finasteride, sold as PROSCAR®, is a 5α-reductase inhibitor mainly used to treat men with benign prostatic hyperplasia (BPH) symptoms with enlarged prostates.

EMA evaluates GSK's Arexvy, an RSV immunization, for approval to protect adults 50-59 with high risk from RSV infection.

Baclofen, sold under the brand name Lioresal among others, is a medication used to treat muscle spasticity such as from a spinal cord injury or multiple sclerosis.

GSK plc announced the European Commission's approval of Omjjara (momelotinib) for market launch. This daily oral drug inhibits both JAK1/JAK2 and activin A receptor type 1.

Ciprofloxacin is a fluoroquinolone antibiotic used to treat a number of bacterial infections. It can be taken by mouth, as eye drops, as ear drops, or intravenously.

Alvotech Reveals Encouraging Preliminary Findings from Drug Behavior Analysis of AVT03, a Potential Equivalent to Prolia® and Xgeva®.

Diphenhydramine (DPH) is an antihistamine and sedative mainly used to treat allergies, insomnia, and symptoms of the common cold.

Oricell has received the green light from the FDA for its investigational new drug (IND) application for OriCAR-017, an innovative CAR-T therapy aimed at GPRC5D.

Tamsulosin was approved for medical use in the United States in 1997. Specifically it is an α1 adrenergic receptor blocker.

Sarepta Therapeutics Reveals Encouraging Results from Segment B in the MOMENTUM Phase 2 Trial for SRP-5051, Targeting Exon 51 Skip-Amenable Duchenne Muscular Dystrophy Cases.